Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Therapure PlasmaCap IG in Adults and Children With Primary Immune Deficiency Diseases

NCT03238079 is registered in ClinicalTrials.gov with Evolve Biologics as lead sponsor.

NCT NCT03238079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03238079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Therapure PlasmaCap IG in Adults and Children With Primary Immune Deficiency Diseases
Lead sponsor
Evolve Biologics
Phase
Phase 3
Overall status
Completed
Start date
September 5, 2017
Completion date
August 25, 2020
Enrollment
63 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency diseases (pidd)